Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 1:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 310 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (microcrystalline cellulose) Clear all
Active, not recruiting Phase 3 Interventional

Psilocybin for Major Depressive Disorder (MDD)

NCT06308653
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
Drug · Behavioral
Lead sponsor
Usona Institute
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 8, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Results available

Alii Supplement Study

NCT07271316
View directory record Official record
Conditions
Nutrient Deficiency, Happiness, Digestive Health, Vulnerability to Disease, Mood Swings, Energy
Interventions
Alii Supplement
Dietary Supplement
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 8, 2026, 1:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion

NCT03480009
View directory record Official record
Conditions
Abortion in First Trimester
Interventions
Dextromethorphan Hydrobromide, Avicel PH101 (Microcrystalline Cellulose NF) for Compounding, Oxycodone
Drug
Lead sponsor
Study Investigator-Sponsor
Other
Eligibility
18 Years and older · Female only
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 8, 2026, 1:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

To Study the Nutri-Genomic Response of Vit-D Supplementation in African-Americans

NCT02802449
View directory record Official record
Conditions
Hypovitaminosis D
Interventions
25 Hydroxy- Vitamin D3 [25 (OH) D3], Placebo
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 70 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 8, 2026, 1:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Alpelisib in Healthy Volunteers

NCT05733455
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Dyslipidemias
Interventions
Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), Placebo (microcrystalline cellulose), 2 capsules, FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage, BOOST Plus nutritional beverage
Drug · Device · Diagnostic Test + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 8, 2026, 1:15 PM EDT
Completed Phase 3 Interventional

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

NCT00449878
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
Liprotamase, Placebo
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 8, 2026, 1:15 PM EDT
Terminated Phase 1 Interventional

Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease

NCT03978156
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Dronabinol 2.5 MG, Microcrystalline cellulose
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 8, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus

NCT01293669
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
TC-6987, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
18
States / cities
Jonesboro, Arkansas • Mountain Home, Arkansas • Buena Park, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 8, 2026, 1:15 PM EDT
Withdrawn Phase 2 Interventional

Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19

NCT04784754
View directory record Official record
Conditions
COVID-19
Interventions
Melatonin, Placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 8, 2026, 1:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)

NCT00950248
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
Idebenone, placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 8, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Results available

Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)

NCT00810368
View directory record Official record
Conditions
Persian Gulf Syndrome
Interventions
Carnosine, Placebo
Drug
Lead sponsor
Georgetown University
Other
Eligibility
34 Years to 82 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 8, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
744 Tablet, 744 LA Injection, Placebo Tablet, Placebo Injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 8, 2026, 1:15 PM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 4 (ACTT-4)

NCT04640168
View directory record Official record
Conditions
COVID-19
Interventions
Baricitinib, Dexamethasone, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
61
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 8, 2026, 1:15 PM EDT
Recruiting Not applicable Interventional

GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women

NCT06813261
View directory record Official record
Conditions
Postmenopause, Metabolism, Geroscience
Interventions
GLYLO, Placebo
Other
Lead sponsor
Buck Institute for Research on Aging
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 8, 2026, 1:15 PM EDT
Completed Phase 1 Interventional

Drug Discrimination in Methadone-Maintained Humans Study 3

NCT01068847
View directory record Official record
Conditions
Drug Dependence
Interventions
2-4 of the drugs listed below
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 8, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Results available

Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection

NCT04818216
View directory record Official record
Conditions
SARS-CoV-2 Infection, Acute Kidney Injury
Interventions
Placebo, Nicotinamide riboside
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
New York, New York • San Antonio, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 8, 2026, 1:15 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Noise-Induced Hearing Loss-Acute Exposure Treatment

NCT04768569
View directory record Official record
Conditions
Hearing Loss, Noise-Induced
Interventions
Zonisamide 100Mg Cap, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 8, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness

NCT06450899
View directory record Official record
Conditions
Acute Mountain Sickness
Interventions
Prochlorperazine Maleate, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Evergreen, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 8, 2026, 1:15 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants

NCT04614714
View directory record Official record
Conditions
Preterm Birth, Inadequate Milk Production
Interventions
Nicotinamide Riboside (NR), Placebo
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 8, 2026, 1:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of IMR-687 in Healthy Adult Volunteers

NCT02998450
View directory record Official record
Conditions
Sickle Cell Disease, Sickle-Cell; Hb-SC, Sickle Beta 0 Thalassemia
Interventions
IMR-687, Placebo Oral Capsule
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 8, 2026, 1:15 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)

NCT05275686
View directory record Official record
Conditions
Eustachian Tube Dysfunction
Interventions
Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray, Placebo Nasal Spray
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Sacramento, California • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 8, 2026, 1:15 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Modafinil to Optimize the Performance of Cold-Stressed Sleep-Deprived Personnel

NCT07830056
View directory record Official record
Conditions
Sleep Deprivation, Cold Exposure
Interventions
Modafinil (M), 200 mg Microcrystalline Cellulose
Drug
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
17 Years to 39 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 8, 2026, 1:15 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Acute Effects of Alpha-glycerylphosphorylcholine (A-GPC) on Lower Body Muscular Performance.

NCT07397273
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
L-Alpha glycerylphosphorylcholine, Microcrystalline Cellulose
Dietary Supplement
Lead sponsor
Northern Illinois University
Other
Eligibility
19 Years to 29 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
DeKalb, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 8, 2026, 1:15 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Investigations of Botanicals on Food Intake, Satiety, Weight Loss, and Oxidative Stress

NCT01238887
View directory record Official record
Conditions
Obesity, Oxidative Stress
Interventions
Microcrystalline Cellulose placebo pill, Garcinia cambogia-derived hydroxycitric acid (2800 mg/day), Garcinia Cambogia derived Hydroxycitric Acid
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
50 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 8, 2026, 1:15 PM EDT